AUS
NZ
UK
CA
USA
IND
Highlights:
- Four-Year Agreement: Moderna will supply its mRNA COVID-19 vaccine to 17 participating countries in the EU, Norway, and North Macedonia.
- Prefilled Syringe Availability: The contract includes the option for prefilled syringes, a preferred format for healthcare providers that improves vaccination efficiency and reduces errors.
- Updated Spikevax Approval: In September 2024, Moderna's updated Spikevax formulation, targeting the SARS-CoV-2 variant JN.1, received marketing authorization in the EU for individuals aged six months and older.
Moderna, Inc. (NASDAQ:MRNA) has announced a major tender win for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway, and North Macedonia, providing vaccine access for up to 17 countries over the next four years.
Supply Agreement Details
The newly awarded tender enables 17 countries to access Moderna’s mRNA COVID-19 vaccine over the next four years. This agreement provides flexibility in vaccine presentation, including prefilled syringes—a format that healthcare providers favor due to its efficiency and reduced risk of administration errors. By streamlining vaccination campaigns, the prefilled syringe format is expected to support large-scale immunization efforts across the region.
Moderna's continued partnership with European health authorities highlights the importance of sustained COVID-19 vaccination campaigns, particularly as the virus evolves and new variants emerge.
Updated Spikevax Authorization
In September 2024, the European Commission granted marketing authorization for Moderna’s updated Spikevax vaccine. This new formulation targets the SARS-CoV-2 JN.1 variant and is authorized for active immunization against COVID-19 in individuals aged six months and older. The updated vaccine is expected to play a critical role in ongoing efforts to curb the spread of new variants and protect vulnerable populations.
About Moderna
Moderna is a global leader in mRNA medicine, pioneering advancements in the field to transform how diseases are treated and prevented. By leveraging its innovative mRNA technology, Moderna is reimagining the future of medicine and enabling the development of groundbreaking solutions for global health challenges.
